Raymond James Financial
BCRX icon

Raymond James Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

Raymond James Financial’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Sell
155,544
-4,987
-3% -$45.1K ﹤0.01% 3686
2026
Q1 		$1.53M Buy
160,531
+29,428
+22% +$229K ﹤0.01% 3554
2025
Q4 		$1.02M Buy
131,103
+26,001
+25% +$188K ﹤0.01% 3755
2025
Q3 		$798K Buy
105,102
+16,610
+19% +$138K ﹤0.01% 3832
2025
Q2 		$793K Buy
88,492
+76,815
+658% +$715K ﹤0.01% 3723
2025
Q1 		$87.6K Buy
11,677
+1,007
+9% +$8.12K ﹤0.01% 4562
2024
Q4 		$80.2K Buy
+10,670
New +$81K ﹤0.01% 4557

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Raymond James Financial's BCRX Position: Q2 2026 in Review

Raymond James Financial reduced its BioCryst Pharmaceuticals (BCRX) stake by 3.1% in Q2 2026, selling an estimated $45.1K and leaving 155,544 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #3686.

Raymond James Financial first reported a position in BCRX in Q4 2024 and has held it in 7 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Raymond James Financial held 155,544 shares of BioCryst Pharmaceuticals worth $1.56M as of Q2 2026.
  • Raymond James Financial sold 4,987 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $45.1K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3686 holding.
  • Raymond James Financial first reported a position in BioCryst Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.